Clients no longer seek CDMOs simply to manufacture batches. They seek partners who strengthen the CMC decisions that shape technical, regulatory, and commercial success. Altruist Biologics' roots within Innovent give us a distinct perspective: we have developed and manufactured biologics as an innovator while supporting external partners as a CDMO. That dual experience shapes our integrated CMC strategy and the high-value technical services we provide for complex biologics, including high-concentration formulation, ADC bioconjugation, process intensification, presentation changes (vial to prefilled-syringe or autoinjector), and comparability strategy. 

In this recent Genetic Engineering & Biotechnology News (GEN) CDMO Roundup article, our Chairman and CEO, Dr. Kaisong Zhou, contributed his perspective on the importance of flexibility, technical expertise, and a strong collaborative partnership in helping biopharma companies navigate increasingly complex development and manufacturing needs.

At Altruist Biologics, we believe the right CDMO should do more than provide capacity — it should work alongside clients to adapt to the unique needs of each program and help move therapies forward with confidence.

Read the article on GEN to see our full insights.